Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.

Bunch TJ, Anderson JL.

Am J Cardiovasc Drugs. 2014 Apr;14(2):89-100. doi: 10.1007/s40256-013-0056-x. Review.

PMID:
24288157
2.

A convenient method to produce [(14) C]carbon monoxide and its application to the radiosynthesis of [carboxyl-(14) C]celivarone, [carboxyl-(14) C]SSR149744.

Whitehead DM, Hartmann S, Ilyas T, Taylor KR, Kohler AD, Ellames GJ.

J Labelled Comp Radiopharm. 2013 Feb;56(2):36-41. doi: 10.1002/jlcr.3009.

PMID:
24285280
3.

Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.

Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Kowey PR.

J Cardiovasc Electrophysiol. 2012 May;23(5):462-72. doi: 10.1111/j.1540-8167.2011.02234.x.

PMID:
22171925
4.

Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.

Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators..

Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561.

5.

Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions.

Gojkovic O, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN, Kowey PR.

Heart Rhythm. 2012 Feb;9(2):217-224.e2. doi: 10.1016/j.hrthm.2011.09.073.

PMID:
21978965
6.

Recent advances in the pharmacological treatment of cardiac arrythmias.

Gramley F, Himmrich E, Mollnau H, Theis C, Hammwohner M, Goette A.

Drugs Today (Barc). 2009 Nov;45(11):807-24. doi: 10.13581/dot.2009.45.11.1412574. Review. Erratum in: Drugs Today (Barc). 2010 Jan;46(1):69.

PMID:
20126673
7.

New pharmacological agents for arrhythmias.

Mason PK, DiMarco JP.

Circ Arrhythm Electrophysiol. 2009 Oct;2(5):588-97. doi: 10.1161/CIRCEP.109.884429. Review. No abstract available.

8.

Alternatives to amiodarone: search for the Holy Grail.

Verma A.

Europace. 2009 Apr;11(4):402-4. doi: 10.1093/europace/eup042. No abstract available.

PMID:
19223364
9.

A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.

Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ.

Europace. 2009 Apr;11(4):458-64. doi: 10.1093/europace/eun384.

10.

Gateways to clinical trials.

Tomillero A, Moral MA.

Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31.

PMID:
18773127
11.

Benzofuran derivatives and the thyroid.

Han TS, Williams GR, Vanderpump MP.

Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13. doi: 10.1111/j.1365-2265.2008.03350.x. Review.

PMID:
18727707
12.

New antiarrhythmic treatment of atrial fibrillation.

Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD.

Expert Rev Cardiovasc Ther. 2007 Jul;5(4):707-14. Review.

PMID:
17605649
13.

In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.

Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D.

J Cardiovasc Pharmacol. 2005 Feb;45(2):125-35.

PMID:
15654261
14.

In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects.

Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, Herbert JM, Nisato D.

J Cardiovasc Pharmacol. 2004 Aug;44(2):244-57.

PMID:
15243307
Items per page

Supplemental Content

Loading ...
Support Center